When soft tissue is damaged, the cells separate to prevent the transmission of infection. The cells leak fluid and cellular components break down while the cellular debris causes inflammation, swelling and pain. ActiPatch stabilizes the leaking cell membrane by recharging it. The pulsed energy delivered by ActiPatch drives of the edematous fluid along with by products of the damaged tissue thereby reducing swelling. The mechanisms provide an environment in which cell-cell communication is re-established in the area of the injured tissue. This provides a well demonstrated and significant overall improvement in the restorative and recovery process following surgery. As a result of the above changes, a decrease in the pain associated with soft tissue injury often occurs.

This patented technology is based on clinically proven, widely accepted PEMF or commonly called: pulsed electromagnetic frequency therapy. The clinical effectiveness of the product has been well established with testings performed at the Bioelectromagnetics Research Laboratory at the State University of New York that have shown that the ActiPatch Therapy provides an adequate dosage of electromagnetic energy for the treatment of soft tissue, and that its power at the skin level is equivalent to that of traditional high-power devices. The power level is six to nine orders of magnitude higher than that which is required to show a biological effect. It also demonstrated that the cumulative effect of continuous delivery provides a greater therapeutic benefit than sporadic treatments.